Begin main content

latanoprost

Last Updated: December 8, 2017
Result type: Reports
Project Number: SR0541-000
Product Line: Common Drug Review

Generic Name: latanoprost

Brand Name: Monoprost

Manufacturer: Laboratoires Théa

Indications: glaucoma and ocular hypertension

Submission Type: New

Project Status: Active

Biosimilar: No

Fee Schedule1: Schedule A

Key Milestones2

Call for patient input posted3September 26, 2017
Patient group input closed3November 15, 2017
Clarification:

- No patient input submission received

Submission receivedOctober 25, 2017
Submission accepted for reviewNovember 08, 2017
Review initiatedNovember 09, 2017
Draft CDR review report(s) sent to applicantFebruary 01, 2018
Comments from applicant on draft CDR review report(s) receivedFebruary 12, 2018
Redaction requests from applicant on draft CDR review report(s) receivedFebruary 20, 2018
CDR review team's comments on draft CDR review report(s) sent to applicantMarch 09, 2018
Canadian Drug Expert Committee (CDEC) meetingMarch 21, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansApril 03, 2018
To
April 05, 2018

Tags

eye